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From the Editor 
 
In recent years, leading health organisations have developed evidence-based guidelines to underpin 
management of health issues.  The Dietitians Association of Australia (DAA) is committed to the 
promotion and enhancement of best practice in Dietetics in Australia and the publication of this 
supplement is a landmark effort in this regard. It will act as a useful resource for the continuing of 
competency standards as well as the credentialing process for the Accredited Practising Dietitians 
(APDs), Advanced APDs and Fellows professional development progam. 
 
The National Health and Medical Research Council (NHMRC) states that evidence based 
guidelines are needed “to improve the quality of health care, to reduce the use of unnecessary, 
ineffective or harmful interventions, and to facilitate the treatment of patients with maximum 
chance of benefit, with minimum risk of harm, and at an acceptable cost”1 (p1). On a practical level, 
dietetic evidence-based practice guidelines will assist APDs to access, and more consistently utilise, 
the best available evidence and specialised treatment recommendations in an information-rich 
environment. 
 
Through the work of the Practice Advisory committee (PAC), DAA has given its endorsement to 
the guidelines published here, there are others waiting in the wings reflecting years of invested time 
and effort by volunteer members. PAC developed guidelines for the endorsement process, provided 
mentors and education to development groups, and appraised guidelines in order to recommend 
endorsement by the DAA Board. The rigorous, transparent guideline development process reflects 
processes recommended by leading research bodies such as the NHMRC. Consultation processes 
involves a large number of people, ideally patients or support groups, peer group Dietitians, and 
other health professionals from relevant fields. In 2005 a format for guidelines publication was 
developed by the DAA National Office so that each set of guidelines published in the journal have a 
standard format that enables dietitians to readily access the same information quickly and easily.  
 
The Cancer Cachexia were developed by an expert groups of Australian dietitians experienced in 
the area (Cancer Cachexia Steering Committee). The Chronic Kidney Disease guidelines represent 
the collaborative efforts of Australian and New Zealand dietitians (Australian New Zealand Renal 
Guidelines Taksforce) who summarized the nutrition elements of five sets of existing guidelines 
from leading international agencies. 
 
The publication of these guidelines represent another milestone in the development of the Dietetics 
profession in Australia and New Zealand and we look forward to this as an ongoing exercise 
extending across the reach of practice, subject to continual update and review. 
 
Linda C Tapsell PhD FDAA 
Editor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. National Health and Medical Research Council. A guide to the development, implementation and 
evaluation of clinical practice guidelines. Canberra: Commonwealth of Australia; 1999. 
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EVIDENCE BASED PRACTICE GUIDELINES FOR NUTRITIONAL MANAGEMENT OF 
CANCER CACHEXIA 
 
INTRODUCTION 
 
Scope and Purpose 
The purpose of these guidelines is to provide dietitians in Australia with a user-friendly summary of 
the evidence to support the nutritional management of adult patients with cancer cachexia. This best 
available evidence is presented and used as a basis for providing recommendations about clinical 
practice.  
 
The clinical questions were as follows: 
• How should patients be identified for referral to the dietitian in order to maximise nutritional 
intervention opportunities?  
• How should nutritional status be assessed? 
• What are the goals of nutrition intervention for patients with cancer cachexia? 
• What is the nutrition prescription to achieve these goals?  
• Should eicosapentaenoic acid be included in the prescription? 
• What are effective methods of implementation to ensure positive outcomes? 
• Does nutrition intervention improve outcomes in patients with cancer cachexia? 
 
This document is a general guide to appropriate practice to be followed only subject to the 
dietitian’s judgement in each individual case. The guidelines are designed to provide information to 
assist decision-making and are based on the best information available at the date of compilation. 
The guidelines recommend intensive nutrition therapy. This has potential resource implications that 
may include additional staff, change to staff roles and increased use of high/protein energy 
supplements if they are considered.  Therefore, in applying the guidelines these potential 
organisational and cost barriers need to be considered. These guidelines for practice are provided 
with the express understanding that they do not establish or specify particular standards of care, 
whether legal, medical or other. 
 
Methods 
A Steering Committee of dietitians with research expertise in nutritional management of cancer 
cachexia and evidence based guideline development produced the first draft of the clinical practice 
guidelines. Initial members of the guideline development team convened in December 2003 were 
Dr Judy Bauer (Chairperson - The Wesley Hospital, Brisbane), A/Prof Susan Ash (Queensland 
University of Technology, Brisbane) and Ms Wendy Davidson (Princess Alexandra Hospital, 
Brisbane). This group developed the initial draft and workshop presentation.  Additional members 
of the team from August 2004 were Ms Jan Hill (Royal Brisbane & Women’s Hospital, Brisbane), 
Ms Teresa Stock (Royal Brisbane & Women’s Hospital, Brisbane), Dr Elisabeth Isenring (Flinders 
University, Adelaide) and Dr Marina Reeves (Queensland Cancer Fund, Brisbane). 
 
The draft was modelled on other guidelines developed for the nutritional management of disease. A 
workshop of dietitians was convened at the 22nd National Conference of the Dietitians Association 
of Australia in May 2004 to consider the draft guidelines and provide peer review. Participants 
evaluated the guidelines using the Appraisal of Guidelines for Research and Evaluation (AGREE) 
instrument (The AGREE Collaboration). 18 Participant feedback from the workshop was 
incorporated into a second draft. The second draft of the guidelines was presented at a workshop for 
dietitians in Perth in November 2004, where again evaluation was completed using the AGREE 
tool. Participant feedback from the workshop was incorporated into the third draft. At both 
workshops case studies were presented to demonstrate the use of the guidelines. A statistician was 
consulted to clarify issues related to levels of evidence and incorporation of evidence from post –
hoc analyses of randomised trials.   
 
The relevant articles were identified by electronic database searches (up to and including April 
2005). The reference lists of relevant articles were also hand searched for any additional studies. In 
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areas where cachexia-specific data was lacking, results from studies of other groups of patients with 
cancer have been included, and identified as such. 
The following search strategies were used for the electronic databases listed below. Details of the 
search results were retained by the guideline development team. 
 
Search terms 
Term 1 Cancer or neoplasm or carcinoma or tumour 
Cancer* or neoplasm* or carcinoma or tumo?r 
Term 2 Cachexia or cachectic or weight loss or malnourished or wasting 
Cachex* or cachect* or (weight los*) or malnourished or wast* 
Term 3 Nutrition or diet 
Nutrition* or diet* 
Search = Terms 1 and 2 and 3 
Limited to adult humans 
Search updated with databases available April 2005 
Electronic 
databases 
The Cochrane Database of Systematic Reviews 
The Cochrane Central Register of Controlled Trials (CENTRAL) 
Medline Advanced 1950 – 2005/01 
PubMed (to include early 2005 publications) - Cancerlit 
CINAHL (1982-current) 
Web of Science  
EMBASE  
Health Source: Nursing/Academic Edition 
Cancernet 
Cancer Spectrum 
Australasian Medical Index (AMI) 
 
The strength of the evidence was assessed using the level of evidence rating system recommended 
by the National Health and Medical Research Council (NHMRC) publication A Guide to the 
Development, Implementation and Evaluation of Clinical Practice Guidelines.19A table was 
developed to collate the evidence for screening, assessment, intervention and monitoring and 
evaluation against key outcome indicators. Levels of evidence, quality of study design, the strength 
of the effect and relevance to practice were considered in ranking the evidence.  
 
The evidence rating system used in the guidelines is as follows: 
 
Level I Evidence obtained from a systematic review of all relevant randomised 
controlled trials 
Level II  Evidence obtained from at least one properly designed randomised 
controlled trial 
Level III-1 Evidence obtained from well-designed pseudo-randomised controlled trials 
(alternate allocation or some other method) 
Level III-2 Evidence obtained from comparative studies with concurrent control and 
allocation not randomised (cohort studies), case-control studies, or 
interrupted time series with a control group 
Level III-3 Evidence obtained from comparative studies with historical control, two or 
more single arm studies, or interrupted time series without a parallel group 
Level IV Evidence obtained from case studies, either post-test or pre- and post-test.19
 
For intervention studies, Level I is recommended as the gold standard. It was felt that clinical 
nutrition studies are difficult to complete in a blinded fashion and often the group most likely to 
benefit from the intervention is excluded for ethical reasons. For these reasons, recommendations 
based on lower levels of evidence but with strong quality of design, strength of effect and relevance 
has been included. 
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The guideline development team also used the NHMRC additional levels of evidence and grades for 
recommendations for developers of guidelines - Pilot Program. 20 This grading system for 
recommendations has been developed as an interim measure to assist guideline developers in 
assessing the entire body of evidence and indicating the strength of each guideline recommendation.  
The grades of recommendation are: 
 
Level A Body of evidence can be trusted to guide practice 
Level B Body of evidence can be trusted to guide practice in most situations 
Level C Body of evidence provides some support for recommendation(s) but care 
should be taken in its application 
Level D Body of evidence is weak and recommendation must be applied with 
caution.20 
 
The five components that are considered in judging the body of evidence are the volume of 
evidence, consistency of the results, potential clinical impact of the proposed recommendation, the 
generalisability of the body of evidence to the target population of the guideline and the 
applicability of the body of evidence to the Australian healthcare context. A recommendation 
cannot be graded as A or B unless the volume and consistency of the evidence components are both 
graded A or B. 
 
Consultation process 
The third draft underwent additional peer, expert and consumer review. It was distributed to 
previous workshop participants, DAA oncology experts, DAA oncology interest groups, 
international dietitians who had expressed an interest in participation, oncologists, nurses, other 
professionals working in the area of cancer and consumers for additional comment. Participant 
feedback was incorporated into a final draft, which was endorsed by the DAA Practice Advisory 
Committee (September 2005) and the DAA Board (November 2005). 
 
Review Process 
The guidelines should be reviewed every three years to ensure they remain current. Responsibility 
for review lies with the guideline development team. Next Review Date: 2008. 
 
Applicability 
A number of workshops were held during the development stage to identify the applicability of the 
guidelines for dietitians in the practice area of cancer. These workshops included: the 22nd National 
Conference of the Dietitians Association of Australia in May 2004; and in Perth in November 2004. 
Once the guidelines had been endorsed a further workshop was held in Queensland in March 2006, 
sponsored by Queensland Health, for dietitians to apply the guidelines to particular case studies. 
Evaluation from all three workshops indicated that the guidelines were applicable for dietetic 
practice. 
 
Editorial Independence 
The guidelines were developed without the assistance of external funding. Where guideline 
development team members were authors of a published article, other members of the guideline 
development team evaluated the article for levels of evidence. Guideline development team conflict 
of interest declarations are: off label research support (Abbott: J, Bauer, S. Ash, W. Davidson) and 
support for conference attendance (Abbott: J, Bauer, S. Ash, W. Davidson; Novartis: J. Bauer, E. 
Isenring). The workshops conducted in 2004 at the DAA Conference in Melbourne and Perth were 
externally sponsored. The views or interests of the workshop sponsors have not influenced the final 
recommendations.  
 
EVIDENCE BASED PRACTICE GUIDELINE FRAMEWORK 
 
 
Figure 1. Framework for evidence based practice guidelines development for the nutritional 
management of cancer cachexia 
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(Adapted from Hakel-Smith & Lewis, 1 and Splett, 2)  
 
 
 
 
 
Appropriate Access to Care  
 
• nutrition screening 
• nutrition assessment 
 
Quality Nutrition Care 
 
• nutrition intervention 
o establishing goals 
o nutrition prescription 
o Implementation 
 
Nutrition Monitoring and Evaluation 
 
• measure and evaluate outcomes 
o intermediate 
o clinical/cost/patient 
 
How should patients be identified for referral to 
the dietitian in order to maximise nutritional 
intervention opportunities?  
 
How should nutritional status be assessed? 
What are the goals of nutrition intervention for 
patients with cancer cachexia? 
 
What is the nutrition prescription to achieve 
these goals?  
 
Should eicosapentaenoic acid be included in 
the prescription? 
 
What are effective methods of implementation 
to ensure positive outcomes? 
 
Does nutrition intervention improve outcomes 
in patients with cancer cachexia? 
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EVIDENCE BASED STATEMENTS 
 
The evidence based statements are listed under headings based on the nutrition care process. 
 
1. Access to Appropriate Care 
 
Nutrition Screening 
 
Clinical question 
 
How should patients be identified for referral to the dietitian in order to maximise nutritional 
intervention opportunities? 
 
Evidence Statement Level of Evidence 
The Malnutrition Screening Tool (MST) is an effective screening tool 
for identifying nutritional risk in cancer patients 
 
Level III-33 
 
Nutrition Assessment 
 
Clinical question 
 
How should nutritional status be assessed? 
 
Evidence Statement Level of Evidence 
Subjective Global Assessment (SGA) is a valid method of assessing 
nutritional status in patients with cancer cachexia 
IV4 
 
The scored Patient-Generated Subjective Global Assessment (PG-SGA) 
is a valid method of assessing nutritional status in patients with cancer 
cachexia 
III-34,5 
Bioelectrical impedance analysis is not suitable for body composition 
measurement in individual patients with cancer cachexia 
III-36,7 
 
2. Quality Nutrition Care 
 
Nutrition Intervention 
 
Establishing goals 
 
Clinical question 
 
What are the goals of nutrition intervention for patients with cancer cachexia? 
 
Evidence Statement Level of Evidence 
Weight-losing patients with cancer cachexia who stabilise their weight 
have greater quality of life and survival duration than those who 
continue to lose weight 
III-28 
 
Nutrition Prescription 
 
Clinical question 
 
What is the nutrition prescription to achieve these goals? 
 
Evidence Statement Level of Evidence 
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Energy and protein requirements for weight stabilisation are 
approximately 120 kJ/kg/d and 1.4 g protein/kg/d in patients with 
cancer cachexia receiving supportive care 
III-28 
Energy and protein requirements for weight stablisation are  
approximately 120 kJ/kg/d and 1.4 g protein/kg/d in patients with  
cancer cachexia receiving chemotherapy 
IV4 
Weight stable patients have higher energy intake than weight losing 
patients in patients with cancer cachexia receiving supportive care 
III-28 
Well-nourished patients with advanced cancer have higher energy and 
protein intakes compared to malnourished patients with advanced 
cancer 
IV9 
 
Clinical question 
 
Should EPA be included in the prescription in patients with cancer cachexia? 
 
Evidence Statement Level of Evidence 
The prescription of EPA improves outcomes in patients with  
cancer cachexia 
Level C4,8,10-16 
 
Body of evidence 
provides some 
support for 
recommendation but 
care should be taken 
in its application 
 
Implementation 
 
Clinical question 
 
What are effective methods of implementation to ensure positive outcomes? 
 
Evidence Statement Level of Evidence 
Compliance with a nutrition prescription of 1.5 cans/d of a high 
protein energy supplement ± EPA does not reduce total food intake in 
patients with cancer cachexia receiving supportive care 
III-217 
Consumption of a high protein energy supplement enriched with EPA 
does not reduce total food intake in patients with cancer cachexia 
receiving chemotherapy 
IV4 
Frequent clinician contact (minimum fortnightly) improves clinical 
outcomes in patients with cancer cachexia. 
III-3 4,15 
 
3. Nutrition Monitoring and Evaluation 
 
Measure and Evaluate Outcomes 
 
Clinical question 
 
Does nutrition intervention improve outcomes in patients with cancer cachexia? 
 
Evidence Statement Level of Evidence 
Nutrition intervention improves outcomes in patients  
with cancer cachexia 
 
Level C4,8,10-16 
Body of evidence 
provides some 
support for 
recommendation but 
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care should be taken 
in its application 
 
Table 1. Summary of recommendations for the nutritional management of cancer cachexia 
 
Point of referral Anorexia, weight loss ≥5% in 6 months and MST≥2 
Time for consultation 45-60 mins initially, 15-30 mins follow-up 
Bio-chemistry and Clinical Albumin, blood glucose (for persons with diabetes), 
Hb, CRP, medications including supplements 
Nutrition assessment Weight, PG-SGA, Protein/Energy intake assessment  
Nutrition Intervention Prescription 
Promote high protein (>1.4g/kg/d) and energy 
(>120g/kg/d) intake ± EPA (1.4-2.0g/d) 
Implementation 
Counselling ± supplements, symptom management, 
meal planning and modification, self monitoring,  
Support Liaise with medical and palliative care team, carers 
and family 
Monitoring Weight, PG-SGA, protein/energy intake minimum 
fortnightly. Frequency of monitoring will vary as 
treatment goals change towards endstage. 
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APPENDIX 1: BACKGROUND TO EVIDENCE STATEMENTS AND TIPS 
The majority of cancer patients experience weight loss as their disease progresses and in general, weight loss is 
a major prognostic indicator of poor survival and impaired response to cancer treatment.24 The incidence of 
malnutrition amongst patients with cancer has been estimated at between 40 – 80%.25,26 The prevalence of 
malnutrition depends on the tumour type, location, stage and treatment.27 The consequences of malnutrition may 
include an increased risk of complications, decreased response and tolerance to treatment, a lower quality of life, 
reduced survival and higher health-care costs. 28-30 Cancer cachexia has been implicated in the deaths of 30 to 
50% of all cancer patients, as many die from the wasting associated with the condition. 31 
 
The causes of weight loss in patients with cancer are multifactorial and may be due to symptoms reducing 
intake, treatment related or mechanical obstruction, or cachexia.  Symptoms such as anorexia, depression, 
anxiety, fatigue, early satiety and pain can result in a decreased appetite and food intake. Cancer treatment may 
result in weight loss, for example surgery (malabsorption), radiotherapy (nausea, pain, diarrhoea, mucositis), 
and chemotherapy (nausea, vomiting, diarrhoea, mucositis). Weight loss may be due to mechanical obstruction 
caused by the cancer itself, such as obstruction of the oesophagus causing swallowing problems and reduced 
intake. Appropriate nutrition support provided during radiotherapy can help to overcome some of the nutrition 
impact symptoms and help patients to maintain weight compared with standard practice where patients 
continued to lose weight during radiotherapy treatment. 32 However if the weight loss is due to cachexia, it may 
not be reversible because host intermediary metabolism (carbohydrate, protein and lipid metabolism) is 
abnormal, limiting the success of nutrition intervention. 33  
 
Numerous drug therapies (eg. megestrol, steroids) have been trialled in patients with cancer cachexia to 
stimulate appetite or attenuate metabolic changes. Several trials with synthetic progesterone agents have 
demonstrated a beneficial influence on weight, however this is largely due to an increase in fat mass .34-
36Evaluation of pharmacotherapies is beyond the scope of these guidelines.  
 
The term cancer cachexia is derived from the Greek words kakos and hexis meaning poor condition. Cachexia 
has been defined as a syndrome characterised by the progressive loss of lean tissue and body fat, and losses are 
often in excess to that explained by the associated anorexia. There are often additional metabolic derangements, 
including anaemia, acute phase protein response and alterations in plasma lipid profile. 21 The development of 
cachexia is common in people with solid tumours such as pancreatic, lung, gastric and colorectal cancer. 
 
Weight loss in cancer cachexia is different from the weight loss of starvation or anorexia. This is due to 
accelerated loss of skeletal muscle in relation to adipose tissue, presence of pro-inflammatory cytokines and 
prolonged acute phase protein response (APPR) that contributes to increased resting energy expenditure and 
weight loss. 22 Patients with cancer cachexia experience anorexia, early satiety, weakness, muscle wasting, 
fatigue, anaemia and severe weight loss. In starvation more than three-quarters of the weight lost is from body 
fat and only a small amount from muscle. In cancer cachexia, weight loss arises equally from loss of muscle and 
fat. 23 
  21
There are no definitive methods for diagnosis of cancer cachexia. Clinical signs of anorexia, muscle wasting and 
weight loss of ≥ 5% over 6 months in patients diagnosed with cancer would be expected but clinical judgement 
is required. Weight loss due to mechanical obstruction, treatment or side effects, which would be expected to 
resolve once the obstruction is bypassed/removed or treatment ceased should not be classified as cachexia. 
These patients still require nutrition intervention but the focus of these guidelines is on cancer cachexia. 
 
The patient target group encompasses any adult patient with cancer fulfilling the diagnostic criteria for cachexia.   
 
Appropriate Access to Care 
 
Nutrition Screening 
 
In Australia, hospital inpatients are generally seen by dietitians as a result of referrals by medical or nursing staff 
37. Studies have found the prevalence of malnutrition to be similar between those patients who were referred to a 
dietitian by medical staff and those who were not referred. 38,39 It is recommended that in addition to referrals by 
medical staff, nutrition screening be performed on admission to hospital or in the outpatient setting during the 
planning stages of commencing anti-cancer therapies. 
 
Nutrition screening is the process of identifying patients with characteristics commonly associated with nutrition 
problems that may require comprehensive nutrition assessment (American Dietetic Association (ADA). 40 The 
purpose of nutrition screening is to quickly identify clients who are malnourished or at risk of becoming 
malnourished who would benefit from nutrition support and prioritise resources to those clients who most need 
nutrition support. According to the ADA40 , an effective nutrition screening tool should be: 
• Simple, quick, reliable, valid and inexpensive 
• Easily administered with minimal nutritional expertise 
• Applicable to most patients and designed to incorporate only routine data and tests available on 
admission. 
 
Many nutrition screening tools have been developed to identify clients at risk of malnutrition in the acute care 
setting and the community. Problems identified with numerous published nutrition screening tools include 
requiring specialised nutrition knowledge, biochemical parameters that may not be immediately available, 
requiring complex calculations or not being evaluated in terms of reliability or validity. 37,41 A number of 
reliable and valid nutrition screening tools have been recently published: 
• Malnutrition Screening Tool 3,42  
• Malnutrition Universal Screening Tool 43 
• Mini Nutrition Assessment-Short Form 44 
• Nutrition Risk Screening 45  
 
When selecting an appropriate nutrition screening tool, it is imperative that the tool has been validated in the 
client population in which it is to be applied. The Malnutrition Screening Tool (MST) is a valid screening tool 
for identifying nutrition risk in patients with cancer (Appendix 2)3, 42 No studies have been identified that report 
nutrition screening in patients with cancer cachexia. 
 
Clinical Question 
 
How should patients be identified for referral to the dietitian in order to maximise nutritional 
intervention opportunities? 
 
Evidence Statement Level of Evidence 
The Malnutrition Screening Tool (MST) is an effective screening tool 
for identifying nutritional risk in patients with cancer 
 
Level III-33 
 
Practice Recommendation 
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Identify “at risk” patients in oncology wards and outpatient clinics using a nutrition screening tool such as the 
Malnutrition Screening Tool that has been validated for oncology patients 
 
PRACTICE TIPS: 
 
1. Nutrition assistants, administration or nursing staff may implement the MST.  
2. The MST can be incorporated into admission forms or patient information sheets. 
3. Repeat nutrition screening during treatment at least fortnightly for patients initially screened at low risk. 
4. If a patient has been referred to the dietitian by other methods eg direct referral from medical oncologist, 
nutrition screening is unnecessary – proceed to nutrition assessment. 
 
Nutrition Assessment 
Nutrition assessment is a comprehensive approach to defining nutritional status using medical, nutrition and 
medication histories, physical examination, anthropometric measurements and laboratory data.40 Nutrition 
assessment parameters may be affected by non-nutritional factors resulting in poor sensitivity and specificity.46 
No single parameter is sufficiently sensitive and specific to determine nutritional status and a combination of 
parameters should be used.47 Several nutrition assessment tools have been published which use a combination of 
parameters.  
 
Subjective global assessment 
Subjective global assessment (SGA) determines nutritional status on the basis of a medical history (weight 
change, dietary intake change, presence of gastrointestinal symptoms that have persisted for greater than two 
weeks, functional capacity) and physical assessment (evidence of loss of subcutaneous fat, muscle wasting, 
oedema or ascites). The features are combined subjectively into an overall or global assessment where patients 
are rated as being well nourished (SGA A), moderately or suspected of being malnourished (SGA B) or severely 
malnourished (SGA C).48 
 
Scored Patient-Generated Subjective Global Assessment 
The scored Patient-Generated Subjective Global Assessment (PG-SGA) is an adaptation of SGA specifically 
developed for use in the cancer population (Appendix 3).49 It contains additional questions regarding short term 
weight loss, a more extensive range of nutrition impact symptoms and for each component of the PG-SGA, points 
(0-4) are awarded depending on the impact on nutritional status. Typical scores range from 0-47 with a higher 
score reflecting a greater risk of malnutrition. The PG-SGA score has been correlated with a number of objective 
parameters (% weight loss, body mass index (BMI)), measures of morbidity (survival, length of stay, quality of 
life), has a high degree of inter-rater reproducibility and high sensitivity and specificity when compared with other 
validated nutritional assessment tools.5,29,50-53 A change in score of approximately nine points is required to move 
one global rating category.53 The PG-SGA score may be more sensitive than the global rating to demonstrate 
improvement or deterioration in nutritional status.52 The scored PG-SGA has been recommended as the nutrition 
assessment tool for patients with cancer by the Oncology Nutrition Dietetic practice group of the American 
Dietetic Association.54 In patients with cancer cachexia, two studies report nutritional status based on the global 
categorisation and the PG-SGA score.4,5 
 
Biochemistry Assessment 
Biochemistry may be influenced by disease and treatment and therefore it is important to use clinical judgement 
when interpreting values. For example, serum albumin may be low due to the acute phase protein response. 
However, serum albumin has been shown to be an independent prognostic variable for survival in patients with 
cancer. 55 Patients with raised serum C-reactive protein levels have lower energy intake than those with normal 
levels 56 and there is some evidence that resting energy expenditure may be increased in these patients. 57 
 
Anthropometric Assessment 
A variety of techniques are available to measure body composition such as Dual Energy X-ray Absortiometry 
(DEXA), anthropometric measurements (eg triceps skinfold thickness (TSF); corrected arm muscle area 
(CAMA)), deuterium and bioelectrical impedance analysis (BIA). DEXA and deuterium are expensive methods 
that are impractical in the clinical setting but may be of use in research studies. Serial anthropometric 
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measurements may be useful to monitor change however accredited training in anthropometry is recommended. 
BIA measures tissue conductivity and can be used to assess total body water (TBW) from which fat free mass 
(FFM) can be calculated.  It is important that a BIA prediction equation is used that has been validated in the 
population under study. 58 Studies examining the validation of BIA in cancer patients are limited6,7,59-62 and no 
equation has been developed or validated in patients with cancer cachexia. At a group level, these equations are 
suitable to predict TBW in patients with cancer cachexia but for an individual, they are unsuitable for use. 7  
 
Functional Assessment 
Tools used to assess functional status include Karnofsky Performance Status and Eastern Cooperative Oncology 
Group (ECOG). A variety of tools have been developed and validated to measure quality of life such as the 
European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C3063, Functional Assessment of 
Cancer Therapy (FACT) 64 and the Short Form Health Survey (SF 36). 65 In patients with cancer, the PG-SGA 
score has been shown to be associated with quality of life (EORTC-QLQC30), and therefore can be used to 
predict the direction and magnitude of change in quality of life. 53 
 
Clinical Question 
 
How should nutritional status be assessed? 
 
Evidence Statement Level of Evidence 
Subjective Global Assessment (SGA) is a valid method of assessing 
nutritional status in patients with cancer cachexia 
IV4 
 
The scored Patient-Generated Subjective Global Assessment (PG-SGA) 
is a valid method of assessing nutritional status in patients with cancer 
cachexia 
III-34, 5 
Bioelectrical impedance analysis is not suitable for body composition 
measurement in individual patients with cancer cachexia 
III-36,7 
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Practice Recommendation 
 
1. Use the scored Patient Generated - Subjective Global Assessment (PG-SGA) as the nutrition assessment tool 
in patients with cancer cachexia. 
 
PRACTICE TIPS: 
 
Table 2. Recommended nutrition assessment parameters for patients with cancer cachexia 
 
Nutrition 
Assessment 
Tool 
PG-SGA: Record both the global rating (SGA-A well nourished, SGA-B 
moderately malnourished, SGA-C severely malnourished) and the PG-SGA 
score (1-47), which need to be determined independently. The diagnosis of 
malnutrition is based on the global rating. Nutrition impact symptoms are a 
major component of the PG-SGA score. Some clients with cancer may have a 
high score due to presence of multiple nutrition impact symptoms yet still be 
well nourished. The score is more sensitive than the global rating to 
demonstrate improvement or deterioration in nutritional status and hence can 
be used when the global rating has not changed. The lower the PG-SGA score, 
the better the client’s nutritional status. 
Anthropometry Record height, body weight, body mass index (BMI) 
Due to the prevalence of overweight and obesity, clients with cachexia may 
have a BMI>25 kg/m2 yet still be moderately or severely malnourished due to 
weight loss, reduced intake, functional capacity, presence of nutrition impact 
symptoms, etc. 
Determine lean body mass if technology available -deuterium, DEXA, 
bioelectrical impedance (BIA) – group level only 
Record anthropometric measurements - TSF, CAMA 
Dietary intake Assess dietary intake, especially energy and protein, quantitatively 
Determine use of vitamin/mineral supplements and complementary medicines 
Assess dietary restrictions and beliefs, texture of diet and other barriers to food 
intake, hydration 
Symptoms/side 
effects 
GI symptoms (nausea, vomiting, constipation, diarrhoea, steatorrhea, early 
satiety) 
Appetite and taste changes 
Presence of pain 
Mood change 
Functional 
status and 
quality of life 
 
Determine functional status and level of fatigue, using PG-SGA, Karnofsky 
Performance Scale or Eastern Co-operative Oncology Group. 
PG-SGA score can be used as surrogate measure of quality of life 
Biochemistry Determine: serum albumin 
  C reactive protein 
  Haemoglobin 
  Blood glucose 
Medications Review medications and note if patients is taking analgesics, enzymes, 
laxatives, antiemetics, alternative therapies 
 
Quality Nutrition Care 
 
Nutrition Intervention 
Nutrition intervention is the second stage of the clinical judgements made in the nutrition care process. The key 
aspects of intervention are establishing the goals of treatment, determining the nutrition prescription and the 
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implementation of the nutrition care. The success or otherwise of nutrition intervention depends equally on these 
components. 66 
 
Establishing goals 
Having identified the nutrition problem by assessing and interpreting the evidence and data collected about the 
patient, a judgement about the goals of treatment must be made. Established goals provide the criteria to be 
measured in the outcome evaluation step, where effectiveness of the nutrition intervention is evaluated. 1 
 
When discussing nutrition intervention options with patients and carers, it is important to present realistic 
potential outcomes.  The goals and outcomes of nutrition intervention will be dependent on patient’s diagnosis 
and prognosis. If goal requirements cannot be achieved with oral intake, alternative means of nutrition support 
should be considered. Refer to guidelines for the use of parenteral and enteral nutrition in adult and paediatric 
patients from the American Society of Parenteral and Enteral Nutrition. 67  
 
Traditionally, treatment has focussed on weight gain as the goal of nutrition intervention. Some studies have 
failed to show a positive effect of nutrition intervention when weight gain was the outcome. 13,14,55 Other studies 
using weight stabilisation as an outcome of nutrition intervention have shown positive effects. Weight losing 
patients with advanced gastrointestinal and non-small cell lung cancer whose weight stabilises have a longer 
survival and improved quality of life than those who continue to lose weight. 8,68,69 Weight stabilisation is an 
appropriate goal for weight losing cancer patients provided that life expectancy is at least two months. 8 
 
Continue to reassess stage of treatment and disease, and whether any change to palliative care status. Determine 
level of support from the patients General Practitioner, carer and palliative care team. When a patient is having 
palliative treatment or palliative supportive care at end stage of disease, intensity of dietary intervention may 
need to be adapted. Liaise with patient/family/carers and medical team to determine level of intervention 
required. Unnecessary dietary restrictions can be relaxed (e.g. cholesterol lowering modifications). Discuss 
treatment with patient for indication of satisfaction with intensity of care. 
 
If end stage, the dietitian may advocate for patient with carer or family to reduce intensity of dietary treatment. 
The desired outcomes are maximising patient comfort and maintaining quality of life. In many cases this may 
mean a patient will not meet full nutrition requirements, for example if tube feeding is refused or supplement 
drinks are not liked. Each case should be assessed individually and with full discussion with the team to 
determine new goals of care. Patients in the final weeks of life are unlikely to be able to maintain their lean body 
mass. Any weight gain that does occur at this time is likely to be due to fluid retention. For comfort measures 
refer to DAA paper: Nutrition priorities in palliative care of oncology patients.70 
 
Clinical Question 
 
What are the goals of nutrition intervention for patients with cancer cachexia? 
 
Evidence Statement Level of Evidence 
Weight-losing patients with cancer cachexia who stabilise their weight 
have greater quality of life and survival duration than those who 
continue to lose weight 
III-28 
 
 
Practice Recommendation 
 
1. Weight stabilisation is an appropriate goal for patients with cancer cachexia 
 
PRACTICE TIPS: 
 
1. Nutrition intervention goals should be individualised taking into consideration prognosis, psychosocial 
issues and the patient’s wishes (Table 3). 
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Table 3. Goals of nutrition intervention for patients with cancer cachexia 
Measure Goal 
PG-SGA Reduce or maintain PG-SGA score 
Anthropometry:  
• Weight 
• skin folds, CAMA  (if accredited in measuring 
skin folds)  
• DEXA, deuterium (if available) 
Stabilise weight and lean body mass 
Dietary intake Achieve appropriate current energy and 
protein intake 
Symptoms or side effects identified in the PG-SGA Minimise symptoms which impact on 
nutritional intake and status 
Karnofsky Performance Scale or ECOG  
PG-SGA as surrogate measure of quality of life 
Improve or maintain functional status score  
Improve or maintain quality of life 
Biochemistry  
• Serum albumin 
• C reactive protein   
• Haemoglobin 
• Blood glucose  
Use to interpret current clinical condition 
Medications Ensure symptoms are being medically 
managed 
Other  
• Assess need for texture modification of diet or 
alternative nutrition support 
• Assess social situation and need for education 
of carers/family/other social support e.g. Meals-
on-Wheels 
 
Ensure appropriate nutrition support is 
provided  
Meet energy and protein requirements 
 
Nutrition Prescription 
 
• Protein and Energy Requirements 
Measurement of energy expenditure via indirect calorimetry is the most accurate method for determining 
individuals’ energy requirements. Energy expenditure of patients with cancer has been shown to vary greatly.71-
73 Treatment and disease stage may alter metabolic requirements over time. Energy intakes in excess of 120 
kJ/kg/day have been needed for weight maintenance in some studies of patients with cancer.4,8,25 Protein intake 
is often reduced as the result of taste alterations, poor appetite and fatigue. Protein requirements for advanced 
cancer patients have not been elucidated. However protein intake in excess of 1.4 g/kg/day have been required 
for weight maintenance in some studies of cancer patients. 4,8 
 
• Eicosapentaenoic acid 
 
A novel approach to the nutrition intervention in patients with cancer cachexia has been the prescription of 
pharmacological doses of eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fat. The major dietary 
sources of EPA in Australia are marine oils, seafood, meat and eggs with the average Australian intake at 0.056 
g per day. 74 Studies in both animals and humans have indicated that EPA supplementation reduces production 
of pro-inflammatory cytokines such as interleukin-6, interleukin-1 and tumour necrosis factor and in cultured 
cancer cell lines increases cell death rate.11,75-77 Table 4 summarises studies in relation to EPA supplementation 
(EPA capsules and oral nutrition supplements) in patients with cancer.  
 
Table 4. Summary of studies of role of eicosapentaenoic acid in patients with cancer cachexia 
 
Author 
Year 
Country 
Level of Evidence & 
Study Design 
Patient cancer 
type and 
number 
Method Results Comment 
Wigmore et al11 
 
1996 
UK 
 
Level IV 
 
Observational study 
12 weeks 
18 weight 
losing 
pancreatic 
cancer patients 
Dose escalation study 
to 16g fish oil/day 
max 
(Max-EPA) 
 
Energy intake - NA 
Protein intake - NA 
Weight - ↓ 2.9kg/mth prestudy, ↑ 0.3kg/month 3 mths 
LBM - NA 
Functional capacity - NA 
Quality of Life - NA 
Survival - NA 
Other Patients tolerated median of 12 Max-EPA daily (2.2g EPA + 1.4g DHA).  
No serious toxicity – 25% steatorrhea, some taste aberrations or transient diarrhoea 
Changes in weight accompanied by a temporary sig ↓ APPR and stabilisation REE 
Demonstrated attenuation of weight 
loss in cancer cachexia  
Gogos et al16  
 
1998 
Greece 
Level II 
 
RCT 
 
 
64 patients with 
mixed solid 
tumour types 
 
18g fish oil (Max-
EPA - 
3.06g EPA+2.07g 
DHA) or placebo 
daily 
Energy intake - NA 
Protein intake - NA 
Weight – ns improvement 
LBM - NA 
Functional capacity - ↑ KPS after 40 days in malnourished patients receiving fish oil 
only 
Quality of Life - NA 
Survival -doubled in patients receiving fish oil only 
Other No effect of fish oil on albumin or transferrin.  
No toxicity of fish oil except for mild abdominal discomfort and transient diarrhoea 
Demonstrated high doses of omega 
3 PUFA given with antioxidant 
supplementation 
-prolonged survival in patients with 
cancer 
- ↑ KPS in malnourished cancer 
patients 
 
Burns et al78 
 
1999 
USA 
Level IV 
Observational study 
 
22 weight 
losing cancer 
patients 
Dose escalation study 
of fish oil 
Energy intake - NA 
Protein intake - NA 
Weight - NA 
LBM - NA 
Functional capacity - NA 
Quality of Life - NA 
Survival - NA 
Other Maximum tolerated dose 0.3g/kg/day fish oil = 21 x 1g capsules/day containing 
7.9g EPA + 5.2g DHA for a 70kg male. Dose limiting toxicity was gastrointestinal – 
diarrhoea.  
Demonstrated maximum tolerated 
dose EPA 
Barber et al79 
 
1999 
UK 
Level IV 
Observational study 
7 weeks 
20 weight 
losing 
pancreatic 
cancer patients 
 
 
High protein, energy 
supplement with 
2.18g EPA 
Energy intake - ↑ 372 kcals  
Protein intake - NA 
Weight -↓ 3.2kg/month prestudy; ↑ 1 kg 3 wks, ↑ 2.5 kg 7 wks 
LBM - ↑ LBM  1kg 3wks; ↑ 1.9kg 7 wks 
Functional capacity -  KPS ↑ 10  3 wks; ↑ 10 7 wks 
Quality of Life - NA 
Survival - NA 
Other Median consumption supplement 1.9 cans/day.  
First study to demonstrate positive 
outcomes (weight gain, LBM, KPS, 
energy) with a combination of EPA 
and protein/energy 
Wigmore et al80 
2000 
UK 
Level IV 
 
Observational study 
12 weeks 
26 weight 
losing 
pancreatic 
cancer 
 
Dose escalation study 
of fish oil  to 6g/day 
EPA (95% pure) 
 
Energy intake - NA 
Protein intake - NA 
Weight - ↓ 2kg/month prestudy; ↑ 0.5 kg/mth  4 wks;   
16 patients weight stable or gained weight 12 wks 
LBM - NA 
Functional capacity - NA 
Quality of Life - NA 
Survival - NA  
Other No change in total body water, MAMC, TSF 
APPR stable. EPA supplement well tolerated –some patients had nausea and/ 
steatorrhoea 
Confirmed previous studies that 
doses of EPA to 6g well tolerated 
 
Confirmed EPA was the active 
ingredient in fish oil capsules. 
Fearon et al10 
 
2003 
Level II 
 
RCT 
200 weight 
losing untreated 
pancreatic 
Randomised to high 
protein and energy 
supplement ±  EPA  
Energy intake - ↑224 kcal E v 68 kcal C, ns;  Sig ↑ E baseline to 8 wks only 
Protein intake - ↑15gE v 6g C, ns; Sig ↑ E baseline to 8 wks only 
Weight - –0.37kg E v –0.25 kg C, ns; Sig change baseline to 8 wks E & C; Wt ↑ 
Both E and C supplements 
attenuated weight loss. ↑ LBM in E 
only  
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Multinational  
8 weeks 
cancer patients  correlated with intake cans E only 
LBM -↑ 0.27 E v 0.12 C, ns; ↑ LBM correlated intake cans E only 
Functional capacity - 
Quality of Life - Global E v C, ns; Post hoc analysis ↑ QoL and ↑ wt E only 
Survival -142 days E v 128 days C, ns 
Other  
 
Non compliance with protocol in 
both groups 
 
High dropout rate due to death 
Bruera et al9 
 
2003 
USA 
 
 
 
 
Level 11 
 
RCT 
 
2 weeks 
60 cachectic 
cancer patients 
Randomised to fish 
oil capsules or 
placebo 
(mean dose EPA 1.8 
g)  
Energy intake -↑ 51 kcals E  v ↓ 57 C kcals ns 
Protein intake - NA 
Weight -↑ 0.03 kg E v ↓ 0.89 kg C ns 
LBM - NA 
Functional capacity - KPS ↑ 10.0 E v ↓ 6.9 C ns 
Quality of Life - NA 
Survival - NA 
Other Appetite, tiredness, nausea, well being ns 
No effect of fish oil on outcomes 
but only 2 weeks of treatment  
 
Non compliance with protocol in 
both groups 10% controls high 
EPA levels 
High dropout rate due to 
intolerance of fish oil 
Jatoi et al13 
  
2004 
USA 
 
Level II 
RCT 
 
3 months 
421 weight 
losing  cancer 
patients 
Randomised to EPA 
sup v meg 
ace+control v meg 
ace+EPA sup 
Energy intake - NA 
Protein intake - NA 
Weight - ↑10%: EPA 6% v Meg+ c 18% v Meg+EPA 11% Ns EPA + Meg+c 
P=0.004  
Any ↑: EPA 37% Meg 39 Meg+EPA 45 Ns 
LBM - NA 
Functional capacity - 
Quality of Life - ns 
Survival - ns 
Other  Appetite↑ EPA  63 Meg 69 Meg+epa 66 
Outcome of 10% weight gain in 
cancer patients unrealistic 
Moses et al15 
 
2004 
UK 
Level II 
RCT 
 
8 weeks 
24 weight 
losing 
pancreatic 
cancer 
patients 
Randomised to high 
protein and energy 
supplement ±  EPA 
for 8 weeks 
Doubly labelled 
water to assess PAL 
Energy intake - E 474 kcals v C 166 ns; Baseline change E p<0.05 only 
Protein intake - Sig ↑  E  27 v C 4  
Weight - E  0.0 v C ↓0.2 ns 
LBM - E 0.3 v C 0.6 ns 
Functional capacity - TEE and PAL ns; ↑ PAL baseline – 8 wks E only 
Quality of Life - NA 
Survival - NA 
Other  
First study to demonstrate 
improvement in functional 
outcomes with a combination of 
EPA and protein/energy 
Davidson et al8 
 
2004 
Australia 
 
 
Level III-2 
Post hoc analysis 
RCT 
 
8 weeks 
 
107 pts 
wt losing 
(>1kg) or wt 
stable untreated 
pancreatic 
cancer patients 
High protein and 
energy supplement ± 
EPA  
 
Energy intake - WL 107kJ/kg/day v WS125 P<0.001 
Protein intake -  
Weight - NA 
LBM - NA 
Functional capacity - 
Quality of Life - WS 55 v WL 47.1 P=0.037 
Survival - WS 259 days v WL 164 P=0.019 
Other  
 
Demonstrated that weight 
maintenance suitable goal for 
patents with cancer cachexia and is 
associated with ↑ survival and QoL 
Bauer & Capra4  
 
 
2005 
Australia  
 
Level IV 
 
Observational study 
 
8 weeks 
8 weight losing 
pancreatic and 
non small cell 
lung cancer pts 
receiving 
chemotherapy 
High protein and 
energy supplement ± 
EPA)  
 
Energy intake - ↑ 36 kJ/kg/d 
Protein intake - ↑ 0.3 g/kg/d 
Weight – 2.3 kg – clinically sig 
LBM – 4.4 kg clinically sig 
Functional capacity - KPS ↑ 10 
Quality of Life - ↑ 16.7 
Survival - NA 
Other: ↑ nutritional status PG-SGA score 9 
No change in meal protein or energy intake over 8 wks 
Demonstrated improvement in 
outcomes (dietary intake, QoL, 
KPS) in cachectic patients 
receiving chemotherapy and 
combination of EPA/protein/energy 
Small number patients 
Persson et al12 
 
2005 
Sweden 
Level II 
RCT 
 
8 weeks 
24 weight 
losing untreated 
advanced 
gastrointestinal 
cancer pts 
Randomised to fish 
oil (4.9 g EPA) or 
Melatonin (18 
mg/day) 4 weeks, 
both treatments 
additional 4 weeks 
Energy intake - ↓ 65kcal 4 wks, ↓ 196 8 wks FO; MLT ↑ 187 kcal 4 wks, ↑ 19 kcal 8 
wks (no stats provided) 
Protein intake –  NA 
Weight –38% stable or gain FO; 27% MLT; 63% FO & MLT 
LBM – NA 
Functional capacity - KPS stable FO & MLT; ns between groups 
Quality of Life – stable FO  & MLT, ns between groups 
Weight stablisation 
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Survival - ns 
Other: No biochemical/cytokine changes; ↑ plasma EPA levels 
 
Bauer et al17  
 
2005 
Australia 
 
 
Level III-2 
Post hoc analysis 
RCT 
 
8 weeks 
 
200 untreated 
pancreatic 
cancer patients 
Compliance (C) with 
1.5 cans/day high 
protein and energy 
supplement ± EPA 
compared to non-
compliant (NC) 
 
Energy intake – 30.3 C v 23.0 NC kcal/kg/day   
Protein intake – 1.26 C v 0.90 NC g/kg/day 
Weight – 1.7 kg difference (p=0.052) 
LBM – 44.1 v 43.6 ns 
Functional capacity - NA 
Quality of Life – 56.8 v 52.4 ns 
Survival – NA 
Other: No change in meal protein or energy intake over 8 wks 
 
Compliance with prescription  1.5 
cans/day supplement no effect on 
meal intake 
 
NA – Not assessed; E – experimental product; C – control product; LBM – lean body mass; KPS – Karnofsky Performance Status; QoL – quality of life; PAL – physical activity level ; ns- not significant
The results of studies of supplementation with EPA either in the form of capsules or high 
protein energy supplements enriched with EPA, are inconsistent. Although positive changes 
have been demonstrated in outcomes (improving energy and protein intake, body 
composition, performance status, quality of life) in patients with cancer cachexia receiving 
high protein energy supplements enriched with EPA in open trials (Level IV studies), in 
general these results have not been confirmed in randomised trials (Level II studies). Issues 
such as compliance with the prescription10, duration of intervention 14, appropriate endpoints13 
and the treatment group (supportive care/chemotherapy/mixed therapy) are important to 
consider when evaluating study outcomes. A common weakness of the four randomised 
controlled trials investigating EPA is the limited discussion of dietetic involvement. Therefore 
whether or not patients received dietary counselling, the recommendations and frequency of 
contact were not documented and could also limit the efficacy of EPA or fish oil.  Further 
studies in different patient groups with cancer are required. 
 
A Cochrane review of the role of EPA in cancer cachexia was scheduled for release in 2005. 
The guideline development team produced evidence based statements regarding EPA and 
outcomes and assessed the body of evidence using NHMRC additional levels of evidence and 
grades for recommendations for developers of guidelines - Pilot Program 2005 (Table 5). 20 
 
Table 5. Assessment of eicosapentaenoic acid (EPA) and outcomes from nutrition 
intervention in patients with cancer cachexia 
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What outcomes from nutrition intervention can you expect in patients with cancer 
cachexia? 
 
The prescription of EPA improves outcomes in patients  (Level C: Body of evidence 
provides some support for recommendation but care should be taken in its application 
with cancer cachexia)  
 
Evidence Statement Level of Evidence
Intermediate Outcomes  
Consumption of a high protein energy supplement enriched with EPA 
for 8 weeks increases protein and energy intake (meals + 
supplements). Consumption of a standard high protein energy 
supplement for 8 weeks increases protein and trends towards 
increasing energy intake in patients with cancer cachexia compared 
with baseline 
II10 
Consumption of a high protein energy supplement ± EPA for 8 weeks 
attenuates loss of weight and lean body mass in patients with cancer 
cachexia receiving supportive care 
II10 
Supplementation with EPA capsules or fish oil for at least 4 weeks attenu
weight loss in patients with cancer cachexia receiving supportive care 
III-3 4,11,12 
Consumption of a high protein energy supplement enriched  
with EPA for 8 weeks protein and energy intake and attenuates 
loss of weight and lean body mass in patients with cancer cachexia 
receiving chemotherapy 
IV4 
A higher intake of a high protein energy supplement enriched  
with EPA is associated with increases in body weight and LBM  
in patients with cancer cachexia receiving supportive care 
III-210 
Consumption of a high protein energy supplement enriched with  
EPA ± megestrol acetate (median 12 weeks) does not improve  
weight (≥10% baseline) or appetite better than megesterol  
acetate alone in patients with cancer cachexia receiving supportive  
care/chemotherapy/radiotherapy. 
II13 
Supplementation with fish oil for 2 weeks does not improve appetite, 
energy intake, weight, or fat-free mass compared with placebo in 
patients with cancer cachexia receiving supportive care/chemotherapy. 
II14 
Clinical/Cost/Patient Outcomes  
Consumption of a high protein energy supplement enriched with EPA 
improves total energy expenditure and physical activity level in patients 
with cancer cachexia receiving supportive care 
II15 
Supplementation with fish oil for at least 4 weeks improves 
performance status in malnourished patients with cancer cachexia 
receiving supportive care 
III-216 
Supplementation with fish oil for at least 4 weeks improves survival in 
patients with cancer cachexia receiving supportive care 
II16 
Supplementation with fish oil for 2 weeks does not improve physical 
function compared with placebo in patients with cancer cachexia 
receiving supportive care/chemotherapy 
II14 
Consumption of a high protein energy supplement enriched with EPA 
used alone or in combination with megestrol acetate (median 12 
weeks) does not improve quality of life or survival in patients with 
cancer cachexia receiving supportive care/chemotherapy/radiotherapy 
II13 
Consumption of a high protein energy supplement ± EPA for 8 weeks 
does not improve quality of life or survival in patients with cancer 
cachexia receiving supportive care 
II10 
Weight-losing patients with cancer cachexia who stabilise their weight 
have greater quality of life and survival duration than those who 
continue to lose weight 
III-28 
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Potential Risks EPA 
The draft Nutrient Reference Values for Australia and New Zealand recommend acceptable 
macronutrient distribution ranges to reduce chronic disease whilst still enuring adequate 
micronutrient status. 81 The lower to upper ends of the recommended intake range for omega 3 
fats (DHA:EPA:DPA) are 190 mg/day to 610 mg/day for men and 90 mg/day to 430 mg/day 
for women, where the upper end of the range is based on 90th percentile of current intake.81  
The United States Food and Drug Administration has concluded that fish oil concentrate is 
Generally Recognised As Safe (GRAS) provided that combined intake of EPA and DHA 
from all added sources does not exceed 3 g/person/day.82 Cancer patients consuming 6 g 
EPA/d have reported no adverse effects on platelet counts.80 No studies, however, have been 
conducted specifically on EPA in cancer patients who are using anticoagulants. It is therefore 
advisable to exercise caution with the use of EPA supplements in cancer patients on 
anticoagulant therapies such as warfarin. Use in such situations should be with the knowledge 
and approval of the patient’s doctor. Large dose of fish oil can cause gastrointestinal side 
effects. 11,16 Cod liver and halibut liver oil are not suitable sources of EPA as the doses 
required could provide excess levels of Vitamin A. Dioxin and dioxin like polychlorinated 
biphenyls are environmental contaminates that accumulate in lipid. Fish oils are potentially a 
significant source, so fish oil supplements are purified to meet European commission 
maximum standards for dioxin.83 The main concerns with these toxins relate to long term 
accumulation, as well as the effect on the foetus or breastfed infant. High short-term intakes in 
adults are unlikely to significantly increase total body burden. 83 Fish oil products and 
supplements are not a major source of dietary mercury and no recommendation has been 
made to restrict consumption because of mercury.83,84  
 
Complimentary and Alternative Therapy 
Australian studies have shown that between 22%-52% of patients with cancer use 
complimentary or alternative therapy with up to $2.3 billion spent in 2000.85-87 Evaluation of 
complimentary or alternative therapy is beyond the scope of these guidelines – refer to The 
Cancer Council Australia's 2005 Position Statement on Complementary & Alternative 
Therapies.88 
 
Clinical Questions 
 
What is the nutrition prescription to achieve these goals? 
Should eicosapentaenoic acid be included in the prescription? 
 
Evidence Statement Level of Evidence 
Energy and protein requirements for weight stabilisation are 
approximately 120 kJ/kg/d and 1.4 g protein/kg/d in patients with 
cancer cachexia receiving supportive care 
III-28 
Energy and protein requirements for weight stablisation are  
approximately 120 kJ/kg/d and 1.4 g protein/kg/d in patients with  
cancer cachexia receiving chemotherapy 
IV4 
Weight stable patients have higher energy intake than weight losing 
patients in patients with cancer cachexia receiving supportive care 
III-28 
Well-nourished patients with advanced cancer have higher energy and 
protein intakes compared to malnourished patients with advanced 
cancer 
IV9 
The prescription of EPA improves outcomes in patients with  Level C 
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cancer cachexia Body of evidence 
provides some 
support for 
recommendation but 
care should be taken 
in its application 
 
 
Practice Recommendations 
 
1. Improving energy and protein intake remains the first step in nutrition intervention for 
weight losing cancer patients  
2. If indirect calorimetry is unavailable, aim for an energy intake of approximately 120 
kJ/kg/day.  
3. Aim for a protein intake of approximately 1.4 g/kg/day. 
4. EPA can be considered as a component of nutrition intervention in cancer cachexia but 
patients should first be assessed for suboptimal symptom control or inadequate intake. If 
using EPA, aim for an intake of 1.4 – 2 g EPA/day which needs to be consumed for at 
least four weeks to achieve clinical benefit.  
 
PRACTICE TIPS: 
 
1. An individual’s energy requirements are best determined by measurement of energy 
expenditure (e.g. indirect calorimetry), however in practice this is rarely available. Due to 
high variation in energy expenditure, use clinical judgement with respect to energy 
requirements taking into consideration age, treatment and treatment goals. Regular 
monitoring of intake and weight will determine whether energy needs are being met. 
2. Prior to commencing nutrition support, assess the patient for risk of refeeding syndrome. 
3. EPA: Potential sources include dietary intake, capsules or a high protein energy 
supplement enriched with EPA. To achieve 1.4 – 2 g EPA/day patients need to consume 
at least 8-11 capsules of fish oil (180 mg EPA/capsule), 300 - 400 g oily fish, 310-445ml 
of a high protein energy supplement enriched with EPA (0.45g EPA/100ml) or 
combination of these. 
 
Implementation  
 
The implementation of dietetic care involves counselling of the patient and/or carers to 
maximise food intake and facilitation of optimal symptom control. Counselling, especially in 
conjunction with high protein energy supplements, has been shown to increase intake and 
attenuate weight loss in a range of cancer patients.25,32,89-92A concern expressed by many 
patients is that consumption of high protein energy supplements may reduce their meal intake. 
In patients with cancer, high protein energy supplements have been shown to increase intake 
without negatively impacting on spontaneous food intake.4,17,90 Prognosis, economic 
circumstances and client preferences need to be considered in decisions regarding supplement 
usage.  
 
Nutrition counselling is effective both during phases of active treatment (chemotherapy and 
radiotherapy) and supportive care. Recommended time for initial consultation is 45-60 
minutes and review consultation 15-30 minutes.93 Recent studies in patients with cancer have 
demonstrated effective clinical outcomes with weekly to fortnightly dietetic intervention. 4, 
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10,15,32,91,92 Dietetic practice regarding the implementation of medical nutrition therapy in 
clients with cancer, however, varies considerably, often depending on resources available. 
Further research regarding innovative methods of nutrition implementation such as telephone 
counselling is required. 
 
Clinical Question 
 
What are effective methods of implementation to ensure positive outcomes? 
 
Evidence Statement Level of Evidence 
Compliance with a nutrition prescription of 1.5 cans/d of a high 
protein energy supplement ± EPA does not reduce total food intake in 
patients with cancer cachexia receiving supportive care 
III-217 
Consumption of a high protein energy supplement enriched with EPA 
does not reduce total food intake in patients with cancer cachexia 
receiving chemotherapy 
IV4 
Frequent clinician contact (minimum fortnightly) improves clinical 
outcomes in patients with cancer cachexia. 
III-3 4,15 
 
Practice Recommendations 
 
1. Nutrition counselling assists cancer patients to optimise their intake.  
2. High protein and energy supplements play a valuable role in improving intake and do not 
simply take the place of usual meals.  
3. Regular nutrition intervention improves clinical outcomes 
 
PRACTICE TIPS: 
 
1. Implementation of high protein, high energy dietary advice: 
• Discuss good sources of protein in the diet – meat, fish and poultry, and encourage 
with at least one serve a day. If vegan/vegetarian ensure adequate alternative sources 
of protein. 
• If protein intake is reduced due to taste changes emphasise good oral hygiene, 
encourage with alternative sources of protein – eggs, dairy, legumes and nuts, suggest 
marinating meats in juice or wine to disguise a bitter taste  
• For patients with chewing and swallowing difficulties, ensure protein in adequate in 
texture modified diets e.g. minced meats, pureed meat/chicken/fish, scrambled or 
poached eggs, mashed beans, peanut paste, lentil/bean soups 
• Encourage patients to consider high protein/energy supplements as an essential 
component of treatment. 
• Assess need for alternative nutrition support if oral intake inadequate and liaise with 
medical team regarding options available and discuss with patient. 
 
2. Compliance issues with EPA to consider in implementation: 
• Decreased appetite and nutrition impact symptoms → difficult to consume adequate 
quantities of fish, capsules or supplements;  
• Capsules – number required, large size, side effects (burping, fishy aftertaste, 
tolerance);  
• High protein energy nutrition supplements enriched with EPA– ensure adequate 
quantity consumed each day, consider taste, consider cost;  
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• Need to develop gastrointestinal tolerance to fish oil and high protein energy 
supplements enriched with EPA – gradually increase dose. 
 
3. Use the PG-SGA to identify barriers to food intake and facilitate optimal symptom control: 
• Nausea, constipation, vomiting, diarrhoea, mouth sores, pain - liaise with medical and 
support team and instigate appropriate medical and nutrition treatment 
• Taste changes, early satiety, aversion to smells - use strategies to manage these 
• Dry mouth and/or swallowing problems - modify texture as required and liaise with 
other allied health professional support e.g. speech pathology. 
• The Cancer Councils in each state provide valuable patient resources describing the 
management of nutrition impact symptoms. 
 
4. If patient is using complimentary or alternative therapies, provide appropriate information. 
 
Nutrition Monitoring and Evaluation 
 
Measure and Evaluate Outcomes – Intermediate and Clinical/Cost/Patient 
Nutrition intervention may lead to a variety of outcomes.  Intermediate outcomes include 
changes in dietary intake, symptoms, biochemistry, anthropometric measures or nutrition 
status. These changes will then impact upon and result in clinical, cost and patient outcomes. 
This includes morbidity and mortality, length of hospital stay, functional capacity or quality 
of life.94 A variety of outcomes have been demonstrated in nutrition intervention studies in 
patients with cancer. To date, in cancer cachexia, intervention studies have focused on using 
fish oil or EPA supplements in management of outcomes. Weight stabilisation may improve 
length and quality of life in patients with cancer cachexia.8 The evidence based statements in 
relation to outcomes of nutrition intervention are below. The body of evidence has been 
evaluated using the NHMRC additional levels of evidence and grades for recommendations 
for developers of guidelines - Pilot Program 2005.20 
 
Clinical Question 
 
Does nutrition intervention improve outcomes in patients with cancer cachexia? 
 
Evidence Statement Level of Evidence 
Nutrition intervention improves outcomes in patients  
with cancer cachexia 
Level C 
Body of evidence 
provides some 
support for 
recommendation but 
care should be taken 
in its application 
 
Practice Recommendation 
 
1. A range of outcomes can be measured in patients with cancer cachexia including protein 
and energy intake, appetite, weight, lean body mass, functional status, quality of life and 
survival.  
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2. Consumption of high protein energy supplement enriched with EPA over a period of at 
least 8 weeks improves intake, total energy expenditure and physical activity level and 
attenuates weight loss in patients with cancer cachexia. 
 
3. There is conflicting evidence about whether EPA supplementation can improve quality of 
life, appetite, lean body mass, and survival. This may be due to studies not being 
conducted for long enough (at least 4 weeks) or because improvement rather than 
attenuation was the outcome goal. 
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APPENDIX 2: THE MALNUTRITION SCREENING TOOL© 
 
Have you lost weight recently without trying 
 If no 
If unsure 
0 
2 
If yes, how much weight (kg) have you lost? 
 0.5 – 5.0 
>5.0 – 10.0 
>10.0 – 15.0 
> 15.0 
Unsure 
1 
2 
3 
4 
2 
Have you been eating poorly because of a decreased appetite? 
 No 
Yes 
0 
1 
 
If score 0 or 1  - not at risk of malnutrition 
    score ≥ 2  - at risk of malnutrition   
 
Ferguson M, Bauer J, Banks M, Capra S. Development of a valid and reliable malnutrition 
screening tool for adult acute hospital patients. Nutrition 1999;15:458-464. 
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APPENDIX 3: THE PATIENT GENERATED SUBJECTIVE GLOBAL 
ASSESSMENT (PG-SGA) 
Name:   
Date:   
Medical History A B C 
WEIGHT Usual 
weight…………. 
Current 
weight…….….. 
   
Wt change past 6 
months 
Amount weight 
loss…... 
% weight 
loss…………. 
   
0-<5% loss   *   
5-10% loss    *  
>10% loss     * 
Weight change past 2 
weeks 
 Amount………    
No change; normal 
weight 
  *   
Increase to within 5%   *   
Increase (1 level above)   * *  
No change, but below 
usual wt 
   *  
Increase to within 5-10%    *  
Decrease     * 
DIETARY INTAKE      
No change; adequate   *   
No change; inadequate    *  
Change  Duration of 
change…………... 
   
Suboptimal diet    *  
Full liquid    *  
Hypocaloric liquid     * 
Starvation      * 
Intake borderline; 
increasing 
  *   
Intake borderline; 
decreasing 
   *  
Intake poor; no change    * * 
Intake poor; increasing    *  
Intake poor decreasing     * 
GASTROINTESTINAL 
SYMPTOMS 
     
 Frequency (never, daily, no. of Duration (<2wk,    
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times/week) >2wk) 
Nausea …………………      ………………..    
Vomiting  …………………      .……………….    
Diarrhoea  …………………      ………………...    
Anorexia  …………………      ………………...    
None; intermittent   *   
Some (daily >2 week)    *  
All (daily >2 week)     * 
FUNCTIONAL 
CAPACITY 
     
No dysfunction  Duration of change 
…………….. 
*   
Difficulty with ambulation/normal 
activities 
   *  
Bed/chair-ridden     * 
Change past 2 week      
Improved    *   
No change    *  
Regressed     * 
 
Physical examination A B C 
SUBCUTANEOUS FAT    
Under the eyes Slightly bulging 
area 
 Hollowed look, 
depression, dark 
circles 
Triceps Large space 
between fingers 
 Very little space 
between fingers, or 
fingers touch 
Biceps  Large space 
between fingers 
 Very little space 
between fingers, or 
fingers touch 
MUSCLE WASTING    
Temple Well-defined 
muscle/flat 
Slight depression Hollowing, 
depression 
Clavicle Not visible in 
Males; may be 
visible but not 
prominent in 
females 
Some protrusion; 
may not be all the 
way along 
Protruding/promine
nt bone 
Shoulder Rounded No square look; 
acromion process 
Square look; bones 
prominent 
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may protrude 
slightly 
Scapula/ribs Bones not 
prominent; no 
significant 
depressions 
Mild depressions or 
bone may show 
slightly; not all 
areas 
Bones prominent; 
significant 
depressions 
Quadriceps Well rounded; no 
depressions 
Mild depression Depression; thin 
Calf Well developed  Thin; no muscle 
definition 
Knee Bones not 
prominent 
 Bones prominent 
Interosseous muscle between 
thumb and forefinger 
Muscle protrudes; 
could be flat in 
females 
 Flat or depressed 
area 
OEDEMA (related to 
malnutrition) 
No sign Mild to moderate Severe 
ASCITES (related to 
malnutrition) 
No sign Mild to moderate Severe 
OVERALL SGA RATING A B C 
(Ferguson, Bauer, Banks, Capra, 1996)© 
 
EVIDENCE BASED GUIDELINES FOR THE NUTRITIONAL MANAGEMENT 
OF CHRONIC KIDNEY DISEASE 
 
INTRODUCTION 
 
Scope and purpose 
The purpose of these guidelines is to provide dietitians in Australia and New Zealand 
with a summary of evidence based clinical guidelines related to the dietetic management 
of adult patients with chronic kidney disease. The patient target group is any adult 
patient fulfilling the definition and diagnostic criteria of Chronic Kidney Disease 
(CKD), excluding those with nephrotic syndrome.  These guidelines by definition also 
exclude acute renal failure and transplantation.  
 
The clinical questions were as follows:  
• At what level of GFR should patients be referred to the dietitian in order to 
maximise nutritional intervention opportunities?  
• Which specific measures best reflect nutritional status or change in nutritional 
status in Chronic Kidney Disease? 
• What are the goals of nutrition intervention for CKD?  
• What is (are) the appropriate nutritional intervention(s) to optimise nutritional 
status in Chronic Kidney Disease and prevent malnutrition? 
• What is the optimal method of implementation and follow up to ensure 
nutritional status is maintained or improved? 
 
These guidelines are meant to serve as a general framework for handling patients with 
particular health problems.  It may not always be appropriate to use these guidelines to 
manage clients because individual circumstances may vary.  The independent skill and 
judgement of the health care provider must always dictate treatment decisions.  These 
guidelines for practice are provided with the express understanding that they do not 
establish or specify particular standards of care, whether legal, medical or other1.  
 
Methods 
The Royal Brisbane and Women’s Hospital (RBWH) Nutrition and Dietetics 
Department supported a project dietitian, Helen McLaughlin to undertake the search 
strategy of existing guidelines. An initial team led by Dr Susan Ash, from Princess 
Alexandra Hospital with Helen McLaughlin, Suzie Chesterfield and Helen McCoy from 
RBWH developed the framework and the initial draft, which was circulated to 
Queensland dietitians working in Nephrology Services. This draft was used for 
consultation and evaluation at a workshop of dietitians at the 21st National Dietitians 
Association Australia conference in May 2003. A national panel of experts was defined 
at the conference, the Australia and New Zealand Renal Guidelines Taskforce 
(ANZRGT), who have continued to refine the guidelines as discussed elsewhere (see 
“Consultation Process”). 
 
Relevant guidelines and articles were identified by Medline database and Internet key 
word searches between April 2002 and October 2003. The evidence based practice 
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guidelines for the dietetic management of chronic kidney disease were developed by 
summarising the nutrition components of the following published guidelines: 
• Caring for Australians with Renal Impairment (CARI) Guidelines2 
• Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice 
Guidelines3-8 
• American Dietetic Association (ADA) Medical Nutrition Therapy Evidence-
Based Guides for Practice: Chronic Kidney Disease (non-dialysis) Medical 
Nutrition Therapy Protocol9  
• ADA Guidelines for Nutritional Care of Renal Patients (3rd ed)10  
• European Dialysis and Transplant Nurses Association and European Renal Care 
Association (EDTNA/ERCA) Guidelines for the Nutritional Care of Adult Renal 
Patients11. 
 
Where conflicting guidelines answering the same clinical question existed, the guideline 
with the strongest level of evidence was included.  When conflicting supporting 
evidence was equal in quality and depth, CARI guidelines were selected preferentially 
as more relevant to the local environment. If similar information was proposed from 
more than one set of guidelines, all sources were acknowledged.  Aspects of nutritional 
management not included in any of the guidelines were omitted, however some aspects 
deemed important have been included as practice tips.  Due to the difficulties associated 
with research into nutritional management of kidney disease, an evidence-based 
approach could not be adopted for all aspects. For published guidelines based on 
opinion or agreed best practice without supporting research, recommendations have still 
been included to complete the document but are acknowledged as being open for wider 
variance in practice.  In particular, adherence to process type guidelines may be strictly 
resource dependant. 
 
The selected guidelines were reformatted into the following components: definition of 
disease, diagnostic criteria, clinical questions to be addressed, referral criteria, nutrition 
assessment, nutrition prescription and outcome measures, in line with established 
nutritional management process.  Dietetic management of acute renal failure, 
transplantation, nephrotic syndrome or kidney disease in paediatrics is not included.  
 
These guidelines include information taken from existing sets of guidelines based on 
scientific evidence, and where no evidence exists, published guidelines stating 
consensus opinion from experienced practitioners including dietitians have been 
included.  These guidelines do not address many issues concerning the implementation 
of dietetic practice, such as using groups or individual consultations, educational 
strategies or counselling techniques.  This is beyond the scope of these guidelines and 
neither the evidence nor consensus opinion currently exists to promote one form of 
practice over another.   
 
The Appendices show the definitions and calculations required for the management of 
Chronic Kidney Disease. 
Levels of evidence or opinion have been cited from the above documents and 
referenced in each guideline. Descriptions of the levels of evidence are listed in Table 1. 
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Table 1: Levels of evidence from original sources 
 
Reference Levels of Evidence       
NHMRC12 I II III-1 III-2 III-3 IV  
 Systematic 
Review of all 
relevant 
clinical trials 
At least 1 
properly 
designed 
Randomised 
Clinical 
Trial (RCT) 
Well-designed 
Pseudo-RCT 
Comparative 
studies with 
concurrent controls 
& allocation not 
randomised (Cohort 
studies), case 
control studies, or 
interrupted time-
series with a control 
group 
Comparative 
studies with 
historical control, 
2 or more single-
arm studies, or 
interrupted time-
series without a 
parallel control 
group 
Case series, either 
post-test or pre-
test and post-test 
 
ADA/Splett, 
20001 
 1 II-1 II-2 II-3 III 
  Evidence 
obtained from 1 
or more well-
designed RCT’s 
Evidence 
obtained from 
well designed 
control trials 
without 
randomisation 
Evidence obtained 
from well designed 
cohort or case-
controlled analytic 
studies, preferably 
from more than 1 
centre or research 
group 
Evidence obtained 
from multiple 
time-series studies 
with or without 
intervention, or 
well designed 
studies with 
concurrent 
comparison 
groups, studies 
with dramatic 
results from 
uncontrolled 
experiments 
Descriptive observational studies 
(no control or comparison group), 
case series reports and reports from 
expert committees, opinions of 
respected authorities and 
documented clinical experience 
ADA, 20029  Grade 1  Grade II Grade III  Grade IV 
  Studies of 
strong design 
for answering 
the questions 
 Studies of strong 
design but 
uncertainty attached 
to the conclusion 
Limited studies of 
weak design. 
Evidence from 
studies of strong 
 The support of the 
conclusion 
consists solely of 
the statement of 
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addressed. The 
results are both 
clinically 
important and 
consistent with 
minor 
exceptions at 
most. The 
results are free 
of serious 
doubts about 
generalisability, 
bias, and flaws 
in research 
design. Studies 
with negative 
results have 
sufficiently 
large samples to 
adequate 
statistical power 
because of 
inconsistencies 
among the results 
for different studies 
or because of 
doubts about 
generalisability, 
bias, research 
design flaws or 
adequacy of sample 
size. OR the 
evidence is solely 
of studies from 
weaker designs but 
results have been 
confirmed in 
separate studies and 
are consistent. 
design is either 
unavailable 
because no 
studies have been 
done or because 
the studies that 
have been done 
are inconclusive 
due to lack of 
generalisability, 
bias, design flaws 
or inadequate 
sample size 
informed medical 
commentators 
based on their 
clinical 
experience, 
unsubstantiated 
by the results of 
any research 
studies 
CARI, 20032 Level A  Level B Level C 
 Randomised controlled trials 
and meta analyses 
   Descriptive studies Consensus or 
opinion 
K/DOQI, 
20003 
 Evidence Evidence & 
Opinion 
Opinion 
  Mainly convincing scientific evidence 
limited added opinion 
Descriptive studies Consensus or 
opinion 
K/DOQI, 
20024 
 S  C R O 
 
  Analysis of 
individual 
patient data 
from a single 
large, 
generalisable 
 Compilation 
of original 
articles into 
evidence 
tables 
Review of reviews 
& selected original 
articles 
Opinion 
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study of high 
methodological 
quality (for 
example 
NHANES III) 
Guidelines for Nutritional Care of Renal 
Patients (3rd ed)10 
No levels of evidence or opinion provided 
European Guidelines for the Nutritional 
Care of Adult Renal Patients11 
‘Examination of the scientific literature shows a paucity of evidence on dietary advice in renal failure. 
Therefore the guidelines are based on scientific evidence, where available, and on consensus of what 
constitutes ‘best practice’ where not’ 
Consultation process 
These practice guidelines have undergone several stages of peer and expert review using 
the Appraisal of Guidelines for Research and Evaluation (AGREE) instrument (The 
AGREE Collaboration)12. The rigour of scientific process varies between guidelines. 
The K/DOQI and CARI guidelines have documented systematic search and review 
processes in place, which meet the NH&MRC and AGREE criteria for quality. The 
ADA and EDTNA/ERCA guidelines are less rigorous, but the information extracted 
from these documents is based on expert opinion and is unable to be assessed using an 
evidence based practice tool. 
 
The first draft of these guidelines was presented at the Dietitians Association of 
Australia (DAA) 21st National Conference in Cairns in May 2003 and achieved support 
in principle.  A national panel of experts was defined at the conference, the Australia 
and New Zealand Renal Guidelines Taskforce (ANZRGT) to oversee further 
development and formulation of the final document. Consultation with nephrologists 
and renal nurses was undertaken when the guidelines were presented at the 31st Annual 
Renal Society of Australasia Conference in Brisbane, also in May 2003. The second 
draft was reviewed by the ANZRGT in August 2003 with comments incorporated into 
the final document.  ANZRGT launched the guidelines in Queensland on October 30, 
2003 with the assistance of the Queensland Health Allied Health Core Practice Group.  
Following the launch of the 2003 Guidelines, a workshop was conducted at the DAA 
22nd National Conference in Melbourne in May 2004, on implementing the guidelines, 
and the taskforce gathered feedback from the 6 month pilot period since launching the 
guidelines. Currently, the guidelines are published on the Queensland Health Electronic 
Publishing Service (QHEPS) Internet site and have been endorsed by DAA.  
 
As part of the DAA endorsement process, consumer input was sourced from Kidney 
Health Australia’s regional Advocacy Committees, which are comprised of CKD 
patients.  A standardised feedback form was developed based on recommendations from 
the Queensland Health Charter of Patient Rights 
(http://www.health.qld.gov.au/qhppc/default.asp). Feedback from consultation in two 
states has indicated that overall consumers felt the guidelines provided a standardised 
approach to care, however were concerned that in their current format were too 
technical to be understood by consumers. Consumers would have liked to have been 
involved from the outset and were particularly interested that minority groups such as 
Indigenous people and those from non English speaking backgrounds be considered in 
any educational material and that those in rural and remote areas receive the same 
access to dietetic care as people in metropolitan areas. Discussion at both the National 
DAA workshops in 2003 and 2004 recognised the importance of involving consumers 
particularly from Indigenous backgrounds in the development of education materials. 
 
Review process 
These guidelines are based on other published guidelines and should be reviewed 
annually to ensure they remain current.  Responsibility for review lies with Royal 
Brisbane and Women’s Hospital in conjunction with the Australia and New Zealand 
Renal Guidelines Taskforce. 
Next Review Date: October 2007. 
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Applicability 
The applicability was tested by dietitians at two National workshops and one state 
workshop. The cost of implementing the guidelines was a human resource issue and 
participants in the workshops felt having the guidelines would assist in lobbying for 
more staff for patient management.  
 
Editorial independence 
These guidelines have been developed as a quality activity without external funding, 
therefore there is no external influence on the content of the guidelines. No member of 
the guideline taskforce has any conflict of interest to declare relating to the development 
of these guidelines.  
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EVIDENCE BASED PRACTICE GUIDELINE FRAMEWORK 
 
The framework for evidence based practice in CKD is presented in Figure 1.  
Insert Figure 1 here. SUMMARY OF EVIDENCE-BASED STATEMENTS 
 
The evidence based statements are listed under the headings described in the Nutrition 
Care Process in Figure 1. 
 
Criteria for referral to dietitian 
 
Clinical Question 
 
At what level of Glomerular Filtration Rate (GFR) should patients be referred to 
the dietitian in order to maximise nutritional intervention opportunities? 
 
Evidence Statement Level of Evidence 
CKD Stages 3 and 4  
CKD Stage 3 (GFR 30-59mL/min) Level IV2 
CKD Stage 4 (GFR 15-20 mL/min) Level III4 
Protein energy malnutrition increases with deteriorating kidney 
function and is associated with adverse outcomes 
Level III-24 
Low protein and calorie intake is an important cause of poor 
nutritional status. 
Level III-34 
CKD Stage 5  
CKD Stage 5 (GFR<15mls/min)  
For patients undergoing haemodialysis and peritoneal dialysis, 
nutritional status should be routinely assessed at commencement of 
dialysis and at regular intervals thereafter. 
Level I2, Level III3 
 
Nutrition Assessment 
 
Clinical Question 
 
Which specific measures best reflect nutrition status or change in nutritional status 
in CKD? 
 
Evidence Statement Level of Evidence 
CKD Stages 3 and 4  
Maintained percent (%) oedema-free (dry) actual body weight 
reflects optimal nutritional status. 
Level II2  
 
Body Mass Index (BMI) =18.5-25, reflects optimal nutritional 
status. 
Level IV3  
 
Subjective global assessment (SGA) and % ideal body weight 
(BMI) reflect change in nutritional status. 
Level IV3 
Total body nitrogen, dual X-ray absorptiometry (DEXA) or 
bioelectrical impedance (BIA) reflect long term nutritional 
adequacy. 
Level IV2 
CKD Stage 5  
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Maintained percent (%) oedema-free (dry) actual body weight 
reflect optimal nutritional status.  
Level II2 
Body Mass Index (BMI) =23-26, reflects optimal nutritional status. Level II2 
SGA maintained or improved reflects nutritional status. Level III-32 
Nutritional status of patients on peritoneal dialysis should be 
monitored by methods appropriate to assess total body stores and 
detect early signs of malnutrition, such as normalised  
protein nitrogen appearance (nPNA) >0.9, total  
body nitrogen (TBN) and DEXA within the normal range. 
Level IV2,3 
 
Nutrition Prescription/Intervention 
 
Clinical Question 
 
What are the goals of nutrition intervention for CKD? 
 
Evidence Statement Level of Evidence 
Achieve and maintain desirable weight and adequate nutritional 
status. 
Level III-211 
Optimise status of co-morbidities, blood glucose control in diabetes 
and fluid and sodium control in hypertension, phosphate control in 
hyperparathyroidism, lipid control and weight management. 
Level III-24 
Normalise or stabilise biochemical markers, such as a normalised 
protein appearance (n PNA)≥0.8 g/day in haemodialysis.  
Level III-24 
Normalise or stabilise biochemical markers, such as a nPNA>0.9 
g/day in peritoneal dialysis. 
Opinion4 
Maintain skeletal muscle stores and strength, using subjective 
global assessment (SGA), TBN and DEXA. 
Opinion4 
 
Clinical Question 
 
What are the prescriptions for appropriate nutritional intervention(s) to optimise 
nutritional status in CKD and prevent malnutrition? 
 
Evidence Statement Level of Evidence 
CKD Stage 3  
Energy. Ideal kilojoule/calorie energy intake determined for age, 
gender and BMI and level of physical activity needs to be 
determined. A nutritionally balanced diet with adequate energy 
intake to maintain a healthy weight needs to be prescribed. 
Opinion2 
Protein. A level of protein of 0.75-1.0 g/ideal body weight 
(IBW)/day is recommended. 
CKD Stage 4 
Level I2 
Energy intake of at least 146kJ/kg IBW/day 35 kcal/kg IBW/day) 
with a moderate protein restriction to prevent protein energy 
malnutrition. 
Level II2 
For patients >60 years, an energy intake of 125 kJ/kg IBW/day is 
recommended. 
Level III-23 
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Protein intake for patients with GFR<25 mL/min, should not be 
less than 0.75g/kgIBW/day. At least 50% should be of high 
biological value. 
Level II2 
Phosphate intake restricted to 800-1000mg/day and/or use of 
phosphate binders is serum phosphate >1.49mmol/L  
Opinion8 
and /or serum parathyroid hormone >7.7 pmol/L on more than 2 
consecutive occasions. 
Level II2 
Supplementation. Patients on a restricted protein diet (<0.75g/kg 
IBW/day) should receive thiamine (>1mg/day), riboflavin (1-
2mg/day) and vitaminB6 (1.5-2mg/day). 
Level IV2 
CKD Stages 3 and 4  
Fat/Carbohydrate. Priority should be given to a diet aimed at 
preventing protein-energy malnutrition and reducing fat to <30% of 
daily energy intake with saturated fat limited to <10% energy. 
Carbohydrate should be utilised to make up the balance of required 
energy intake. 
Opinion2 
Sodium intake of <100mmol/day is recommended if the patient is 
hypertensive and CKD is progressive. 
Opinion2 
Potassium intake should be reduced if serum K > 6mmol/L Opinion2 
Phosphate intake restricted to 800-1000mg/day and/or use of 
phosphate binders is serum phosphate >1.49mmol/L and /or 
Opinion8 
serum parathyroid hormone >12.1 pmol/L on more than 2 
consecutive occasions. 
Level III-2/33 
Fluid intake needs to be adjusted to the degree of CKD and 
prevention of renal disease, oedema management and hypertension 
management. Once fluid intake requires diuretics a liberal intake 
should be curbed. Management of hypertension includes limiting 
fluid intake. 
Opinion2 
Vitamin D supplementation is required for patients with 
GFR<50mL/min and PTH level 3-6 times the normal range or 
histological evidence of osteodystrophy. 
Level II2 
CKD Stage 5  
Energy levels of 125-146kJ(30-35 kcal)/kgIBW/day are 
recommended to prevent malnutrition.  
Level IV2 
Energy levels of at least 146 kJ (35kcals)/kgIBW/day is 
recommended for those acutely ill < 60years and 125-146 kJ (30-35 
kcals)/kgIBW/day for those acutely ill >60years. 
Level IV3 
Protein intake is recommended at 1.2-1.4gkg IBW/day, >50% high 
biological value protein.  
Level IV2 
In haemodialysis, protein intake at least 1.2g/kg IBW/day when 
acutely ill.  
Opinion4 
In peritoneal dialysis, protein intake at least 1.3g/kg IBW when 
acutely ill 
Opinion4 
In peritoneal dialysis, protein intake at least 1.5g/kgIBW/day with 
peritonitis. 
Opinion4 
Fat and Carbohydrate <7% energy from saturated fat, 
polyunsaturated fat, monounsaturated fat <20%energy, 
carbohydrate 50-60% energy. 
Level III-27 
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Sodium. Individualised treatment is recommended based on 
oedema and hypertension. 80-110mmol/day if restricted. 
Level IV11 
Phosphate. Restrict intake to 800-1000mg/day if serum phosphate 
>1.8mmol/L,  
Opinion4 
and/or PTH>33.3pmol/L Level III-28 
Fluid. For haemodialysis, restrict fluid to 500mL + previous day’s 
output. 
Level III-211 
For peritoneal dialysis, individualised treatment recommended 
based on oedema and hypertension. If fluid overloaded, 800 mL+ 
previous day’s output recommended.  
Opinion11 
 
Implementation and Management 
 
Clinical Question 
 
What are effective methods of implementation to achieve positive outcomes in 
CKD? 
 
Evidence Statement Level of Evidence 
EDUCATION  
CKD Stage 3  
Patients with decreased dietary intake or malnutrition need dietary 
modification, counselling and specialised nutrition therapy. 
Level IV4 
For patients with poorly controlled co-morbidities, refer to Opinion 
medical specialist. ANZRGT  
CKD Stage 4  
Pre end stage kidney disease education forms an important part of 
management strategy to slow the progression of renal disease and 
may have a beneficial effect. 
Level II2 
Nutrition counselling should encompass appropriate protein and 
energy intake. 
Level III-24 
Nutrition counselling should include fluid, sodium and potassium 
intake  
Level IV2 
and weight management Opinion4 
CKD Stage 5  
Every patient should receive intensive nutrition counselling based 
on an individualised care plan. 
Opinion4 
The care plan should focus on adequate protein and energy intake. Level IV2 
MONITORING AND EVALUATION  
Recommended times for initial consultation are 45-60mins Opinion9 
and review 20-30mins, for all patients.  
CKD Stage 5  
Nutrition reviews for dialysis patients need to occur every Opinion9 
6 months.  
Timing for outcomes to be monitored include:  
• Monthly   
o oedema free body weight and BMI Level II2 
o serum albumin Opinion2 
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• 3-6 monthly, dialysis adequacy (Kt/V) Level IV2 
o nPNA Level IV2 
o Dietary interview Opinion2 
o SGA Level IV2,4 
• 6-12 monthly, assessment of body stores using TBN /DEXA Opinion4 
 
Summary of Recommendations for Management of Chronic Kidney Disease 
CKD Stage 3 (GFR 30-59)4 Stage 4 (GFR 15-29)4 Stage 54 Haemodialysis Stage 54 Peritoneal Dialysis 
Point of 
referral 
GFR<60ml/min2,4 GFR<30ml/min3 Upon commencement Upon commencement 
Time for 
consultation 
45-60 mins9 45-60 mins9 45-60 mins10 45-60 mins10 
Bio-
chemistry 
and Clinical 
Alb4, K9, PO4,9 cr9, bld 
glucose & HbA1c(for 
persons with diabetes) 9, 
PTH8, BP9, lipids2, GFR9, 
Hb9, medications inc 
supplements9 
Alb3, K9, PO49, cr9, bld 
glucose & HbA1c(for 
persons with diabetes)9, 
PTH8, BP139, lipids2, 
GFR9, Hb9, medications 
inc supplements9,  
Pre dial: Alb2,3, urea2, K10, 
PO42, CaxPO42, lipids7, 
PTH8, 
Post dial: urea10 HbA1c (if 
diab)10, HD freq & fluid 
gains104, BP10, 
medications10, Kt/V3 
Alb2,3, K10, PO410, lipids7, 
PTH8, CaxPO42, urea &/or cr2, 
HbA1c (if diab) 10, PD 
prescription & fluid gains10, 
BP10,  medications10, Kt/V3 
Nutrition 
assessment 
 
 
 
dry wt2,4, BMI2, 
%IBW/SGA4, diet 
assessment/nPNA2,4, 
activity level and 
limitations9 
dry wt2,3, BMI2, 
%IBW/SGA3, diet 
assessment/nPNA2,3, 
activity level and 
limitations9 
Dry wt2, BMI2, %IBW3, 
SGA2,3, diet assessment2,3 
or nPNA2,3 
Dry wt2, BMI2, %IBW3, 
SGA2,3, diet assessment2,3 or 
nPNA2,3 
Nutrition 
intervention 
-  Energy 
Ideal for age, gender, BMI 
and phys activity level2 
At least 146kJ/kg IBW 
(BMI 18.5-25) 2, 125-
146kJ/kg IBW >60 yr3 
125-146kJ/kg IBW (BMI 
22-25)2  
acute illness: >146kJ/kg 
IBW if <60yr 3, >125kJ 
/kg IBW if > 60yr3 
146kJ (35kcal)/kg IBW (BMI 
22-25)2 inc glucose from 
dialysate9 
acute illness: >146 kJ/kg IBW 
/day3 
-  Protein 0.75-1.0g/kg IBW/day2 0.75-1.0g/kg IBW2 with 
adequate kJ intake2 
>50% HBV2 
1.2-1.4g/kg IBW2 >50% 
HBV3 
acute illness: > 1.2 g /kg 
IBW3 
min 1.2g/kg IBW2; >50% 
HBV3 acute illness: >1.3g 
/kgIBW3; peritonitis: 1.5g/kg 
IBW11 
-  Sodium <100mmol if hypertensive 
and CKD is progressive2 
<100mmol if hypertensive 
and CKD is progressive2 
80 –110 mmol/day11 Indiv treatment 
recommended, if restricted  
  
54 
 
80-110 mmol/day11 
-  Potassium Not usually restricted, If 
K+ > 6.0 limit intake6 to 
1mmol/kg IBW/ day  
If K+>6.0 limit intake2 to 
1mmol/ kg IBW/day  
1mmol/kg IBW/day10 Indiv treatment 
recommended, if restricted 
1mmol/ kg IBW/day 10 
-  Phosphate if >1.49 mmol/L, (or 
>target PTH) restrict to 
800-1000mg/day (adj for 
protein) &/or binders 8 
if >1.49 mmol/L, (or 
>target PTH) restrict to 
800-1000mg/day (adj for 
protein) &/or binders 8 
if >1.78 mmol/L, (or 
>target PTH) restrict to 
800-1000mg/day (adj 
protein) &/or binders 8 
if >1.78 mmol/L, (or >target 
PTH) restrict to 800-
1000mg/day (adj for protein) 
&/or binders 8 
-  Fluid Individualised based on 
CKD, oedema and 
hypertension2 
Individualised based on 
CKD, oedema and 
hypertension2 
500ml + PDUO11 Indiv treatment 
recommended, if fluid 
overloaded or hypertensive: 
800ml + PDUO11 
Nutrition 
counselling 
adequate protein and 
energy2,4, bld glucose 
control in DM4, fluid and 
Na control in HT4, lipid2 & 
weight4 control, meal 
plan9, self monitoring9, 
physical activity15 
protein and energy 
intake2,3, Na, K & fluid 
intake2, wt control2,9 , meal 
plan9,recipe modification, 
self monitoring9, physical 
activity9 
individual care plan3, 
adequate protein and 
energy intake2, fluid & 
electrolyte management10, 
self monitoring10, meal 
plan10, physical activity10  
individual care plan3, 
adequate protein intake2, 
appropriate energy intake2, 
self monitoring10, meal plan10, 
physical activity10 
Review & 
frequency of 
follow up 
Dry wt & BMI monthly2, 
20-30 min9 r/v every 6-12 
months if no evidence of 
malnutrition, more 
frequently if 
malnourished4 
Dry wt & BMI monthly2, 
20-30 min9 r/v every 1-3 
months2, more frequently 
if inadequate intake, 
concomitant illness, GFR 
< 15 or malnourished3; 
SGA every 6-12 months2 
Dry wt, BMI & alb 
monthly2, 45-60 min10 r/v 
every 3-6 months inc 
nPNA, Kt/V, diet 
assessment & SGA2, more 
frequently if clinically 
indicated2 
Dry wt, BMI & alb monthly2, 
45-60 min10 r/v every 6 
months inc nPNA, Kt/V, diet 
assessment & SGA2, more 
frequently if clinically 
indicated2 
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APPENDIX 1: BACKGROUND TO EVIDENCE STATEMENTS  
Diagnosis and Referral 
Chronic Kidney Disease (CKD) is defined as the presence of kidney damage for 3 
months or more, as defined by structural or functional abnormalities, with or without 
decreased glomerular filtration rate (GFR), OR, GFR less than 60ml/min for more than 
3 months with or without kidney damage2. Kidney damage is defined as pathologic 
abnormalities or markers of damage, including abnormalities in blood or urine tests or 
imaging studies4. 
 
Table 2: Stages of Chronic Kidney Disease 
Stage Description GFR 
(mL/min/1.73m2) 
1 Kidney damage with normal or ↑ GFR ≥ 90 
2 Kidney damage with mild ↓ GFR 60-89 
3 Moderate ↓ GFR 30-59 
4 Severe ↓ GFR 15-29 
5 Kidney failure < 15 (or dialysis) 
 
CALCULATIONS 
Estimated Glomerular Filtration Rate (eGFR) 
Modification of Diet in Renal Disease (MDRD) formula16 
eGFR = 186 × ([SCR/88.4]–1.154) × (age) –0.203 × (0.742 if female) × (1.210 if African-
American) 
NB the African-American factor is not used in Australia 
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where eGFR = estimated glomerular filtration rate (mL/min/1.73m2), SCR = serum 
creatinine concentration (μmol/L), and age is expressed in years. 
An automated calculator for MDRD-based eGFR can be found at 
<http://www.kidney.org.au>. 
As the MDRD formula has not been validated in children, its use should be restricted to 
people over 18 years of age. 
eGFR values over 60 mL/min/1.73m2 should be reported as 
“> 60mL/min/1.73m2”, rather than as a precise figure.  
Specific clinical settings in which eGFR is not appropriate for use and GFR should be 
measured directly include: 
 populations in which the MDRD equation is not validated (eg, Asian 
people) or in which validation studies have not been performed (eg, Aboriginal 
and Torres Strait Islander populations); 
 severe malnutrition or obesity; 
 extremes of body size and age; 
 exceptional dietary intake (eg, vegetarian diet or creatine supplements); 
 disease of skeletal muscle, paraplegia, etc; and 
 rapidly changing kidney function. 
 
Normalised protein nitrogen appearance (nPNA)2 
1. Chronic renal failure 
nPNA may be approximated by the Randerson formula  
nPNA (g/kg/day) = [[urea excretion (mmol/day) x 0.209] + 15.71] ÷ weight (kg)  
 
1. Haemodialysis 
The most widely used method calculates the urea generation rate from the end of the 
first dialysis to/the beginning of the second dialysis and relies predominantly on the 
difference between the post and pre dialysis urea values .  
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Several methods are used to calculate the urea generation rate from which the PNA are 
calculated.  
 
PNA = UGR  (g/24 hrs) + 1.7 + Urinary protein losses 
 0.154  
 
UGR (g/24 hrs) = Urea (mmol/24 hrs) x 0.028 
Note: In all cases urinary urea and protein losses need to be measured and 
included in the calculations used to estimate protein intake. 
 
1. Peritoneal dialysis 
Given that daily changes in body nitrogen are usually negligible in stable patients on 
peritoneal dialysis, the urinary nitrogen appearance (UNA) is usually represented as 
the sum of dialysate and urinary losses. The protein equivalent of total nitrogen 
appearance (PNA) expresses the nitrogen appearance in terms of protein. 
PNA (grams of protein/24hrs) = TNA (grams of nitrogen/24 hrs) x 6.25. 
Because of the constant relationship between the measured UNA and the total nitrogen 
appearance, the protein equivalent of total nitrogen appearance (PNA) is determined 
from the UNA, or from the urea appearance (UA) by the following formulae17. 
PNA (g/day) = 20.1 + 7.5 x UNA (g/24 hrs) 
or 
PNA (g/day) = 20.1 + 0.209 x UA (mmol/24 hrs) 
1. Calculation of Ideal Body Weight (IBW) 
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Aim for weight to be within BMI of 20-25 if GFR 15-59 and a BMI of 23-26 on a 
dialysis modality.  A patient’s ideal body weight can be adjusted (as per the equation 
below), particularly if a patient is obese BMI>30.   
 
Adjusted Body Weight = [(Actual Weight – Ideal Weight) x 0.25] + Ideal Body Weight 
(IBW).  
 
When to use actual or adjusted body weight: 
Use actual body weight (dry weight for dialysis patients) when:  
¾ Weight is within reasonable range of ideal or standard body weight 
(recommended BMI range).   
¾ Recent weight change has not occurred.   
¾ The patient is not malnourished. 
¾ The patient has been slightly overweight or underweight almost all of 
their lives.   
Use adjusted body weight when patients are overweight/obese, using clinical 
judgement.    
 
